|
FY2025
12 months to Sep 30, 2025
|
FY2024
12 months to Sep 30, 2024
|
|
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net loss | ||
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| R&D acquisition paid in equity | ||
| Equity-based compensation | ||
| Amortization of right-of-use assets | ||
| Depreciation | ||
| R&D acquisition paid-in equity | ||
| Changes in fair value of contingent liability | ||
| Change in assets and liabilities: | ||
| Prepaid expenses | ||
| Deposits | ||
| Accounts receivable | ||
| Accounts payable and accrued liabilities | ||
| Due to related parties | ||
| Lease liabilities | ||
| Contingent liability | ||
| Net cash used in operating activities | ||
| INVESTING ACTIVITIES | ||
| In-process research and development | ||
| Increase in long-term investments | ||
| Additions to property, plant and equipment | ||
| Net cash used in investing activities | ||
| FINANCING ACTIVITIES | ||
| Proceeds from common stock issuances | ||
| Offering costs | ||
| Proceeds from exercise of warrants | ||
| Proceeds from stock option exercised | ||
| Payment of deferred offering costs | ||
| Net cash provided by financing activities | ||
| Net increase in cash | ||
| Cash and cash equivalents, beginning of year | ||
| Cash and cash equivalents, end of year | ||
| Non-Cash Supplemental Disclosures | ||
| Right of use assets acquired in exchange for new operating lease liabilities | ||
| Inception of Right-of-Use Asset / Lease Liability |
Loading...
